These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28711713)

  • 21. QIAD assay for quantitating a compound's efficacy in elimination of toxic Aβ oligomers.
    Brener O; Dunkelmann T; Gremer L; van Groen T; Mirecka EA; Kadish I; Willuweit A; Kutzsche J; Jürgens D; Rudolph S; Tusche M; Bongen P; Pietruszka J; Oesterhelt F; Langen KJ; Demuth HU; Janssen A; Hoyer W; Funke SA; Nagel-Steger L; Willbold D
    Sci Rep; 2015 Sep; 5():13222. PubMed ID: 26394756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment with Aβ42 binding D-amino acid peptides reduce amyloid deposition and inflammation in APP/PS1 double transgenic mice.
    van Groen T; Kadish I; Funke A; Bartnik D; Willbold D
    Adv Protein Chem Struct Biol; 2012; 88():133-52. PubMed ID: 22814708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and validation of an UHPLC-ESI-QTOF-MS method for quantification of the highly hydrophilic amyloid-β oligomer eliminating all-D-enantiomeric peptide RD2 in mouse plasma.
    Hupert M; Elfgen A; Schartmann E; Schemmert S; Buscher B; Kutzsche J; Willbold D; Santiago-Schübel B
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1073():123-129. PubMed ID: 29248770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In Vitro and In Vivo Efficacies of the Linear and the Cyclic Version of an All-d-Enantiomeric Peptide Developed for the Treatment of Alzheimer's Disease.
    Schemmert S; Camargo LC; Honold D; Gering I; Kutzsche J; Willuweit A; Willbold D
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs.
    Wang J; Yadav V; Smart AL; Tajiri S; Basit AW
    Mol Pharm; 2015 Mar; 12(3):966-73. PubMed ID: 25612507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stabilities and conformations of Alzheimer's beta -amyloid peptide oligomers (Abeta 16-22, Abeta 16-35, and Abeta 10-35): Sequence effects.
    Ma B; Nussinov R
    Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14126-31. PubMed ID: 12391326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transthyretin stabilization by iododiflunisal promotes amyloid-β peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer's disease mouse model.
    Ribeiro CA; Oliveira SM; Guido LF; Magalhães A; Valencia G; Arsequell G; Saraiva MJ; Cardoso I
    J Alzheimers Dis; 2014; 39(2):357-70. PubMed ID: 24169237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of Alzheimer's disease amyloid plaque load in transgenic mice by D3, A D-enantiomeric peptide identified by mirror image phage display.
    van Groen T; Wiesehan K; Funke SA; Kadish I; Nagel-Steger L; Willbold D
    ChemMedChem; 2008 Dec; 3(12):1848-52. PubMed ID: 19016284
    [No Abstract]   [Full Text] [Related]  

  • 30. Inhibition of amyloid Aβ aggregation by high pressures or specific d-enantiomeric peptides.
    Cavini IA; Munte CE; Erlach MB; van Groen T; Kadish I; Zhang T; Ziehm T; Nagel-Steger L; Kutzsche J; Kremer W; Willbold D; Kalbitzer HR
    Chem Commun (Camb); 2018 Mar; 54(26):3294-3297. PubMed ID: 29537428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High order W02-reactive stable oligomers of amyloid-β are produced in vivo and in vitro via dialysis and filtration of synthetic amyloid-β monomer.
    Robb E; Perez K; Hung LW; Masters CL; Barnham KJ; Cherny RA; Bush AI; Adlard PA; Finkelstein DI
    J Alzheimers Dis; 2015; 44(1):69-78. PubMed ID: 25182735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers.
    Umeda T; Ono K; Sakai A; Yamashita M; Mizuguchi M; Klein WL; Yamada M; Mori H; Tomiyama T
    Brain; 2016 May; 139(Pt 5):1568-86. PubMed ID: 27020329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived β-secretase inhibitors.
    Wood S; Wen PH; Zhang J; Zhu L; Luo Y; Babu-Khan S; Chen K; Pham R; Esmay J; Dineen TA; Kaller MR; Weiss MM; Hitchcock SA; Citron M; Zhong W; Hickman D; Williamson T
    J Pharmacol Exp Ther; 2012 Nov; 343(2):460-7. PubMed ID: 22911925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides.
    He YL; Murby S; Warhurst G; Gifford L; Walker D; Ayrton J; Eastmond R; Rowland M
    J Pharm Sci; 1998 May; 87(5):626-33. PubMed ID: 9572915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The coexistence of an equal amount of Alzheimer's amyloid-β 40 and 42 forms structurally stable and toxic oligomers through a distinct pathway.
    Chang YJ; Chen YR
    FEBS J; 2014 Jun; 281(11):2674-87. PubMed ID: 24720730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MRZ-99030 - A novel modulator of Aβ aggregation: II - Reversal of Aβ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice.
    Rammes G; Gravius A; Ruitenberg M; Wegener N; Chambon C; Sroka-Saidi K; Jeggo R; Staniaszek L; Spanswick D; O'Hare E; Palmer P; Kim EM; Bywalez W; Egger V; Parsons CG
    Neuropharmacology; 2015 May; 92():170-82. PubMed ID: 25637092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular dynamics simulations to investigate the structural stability and aggregation behavior of the GGVVIA oligomers derived from amyloid beta peptide.
    Chang LK; Zhao JH; Liu HL; Liu KT; Chen JT; Tsai WB; Ho Y
    J Biomol Struct Dyn; 2009 Jun; 26(6):731-40. PubMed ID: 19385701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unmodified and pyroglutamylated amyloid β peptides form hypertoxic hetero-oligomers of unique secondary structure.
    Goldblatt G; Cilenti L; Matos JO; Lee B; Ciaffone N; Wang QX; Tetard L; Teter K; Tatulian SA
    FEBS J; 2017 May; 284(9):1355-1369. PubMed ID: 28294556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The new β amyloid-derived peptide Aβ1-6A2V-TAT(D) prevents Aβ oligomer formation and protects transgenic C. elegans from Aβ toxicity.
    Diomede L; Romeo M; Cagnotto A; Rossi A; Beeg M; Stravalaci M; Tagliavini F; Di Fede G; Gobbi M; Salmona M
    Neurobiol Dis; 2016 Apr; 88():75-84. PubMed ID: 26792398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.